Brought to you by:
Deep vein arterialization challenges notion of ‘no-option’ CLTI
“Patients previously considered ‘no-option’ may no longer truly be without options,” said Anahita Dua, MD, associate professor at Harvard Medical School and a vascular surgeon at Massachusetts General Hospital. That assertion sums up the central finding of an analysis comparing…
TADV without venous branch coiling still yields strong limb salvage rates among ‘no-option’ CLTI patients
Transcatheter arterialization of deep veins (TADV) done without the coiling of venous outflow branches achieved sufficient distal perfusion after three months among “no-option” chronic limb-threatening ischemia (CLTI) patients, according to results from a study published in the Journal of Vascular…
Deep vein arterialization: Much remains to be learned but use poised to expand in patients with less severe ischemia
These remain early days for transcatheter arterialization of the deep veins (TADV) in the setting of patients with severe chronic limb-threatening ischemia (CLTI), says Daniel Clair, MD, one of the principal investigators in key clinical trials of the procedure, but…
The role of deep venous arterialization comes under scrutiny
“Every so often in vascular disease, disruptive technologies come along and the question really is, ‘Is this going to make a big impact on patient care?’” These were the words of CX Executive Board member Robert Hinchliffe, MBChB, clinical professor…
Results from PROMISE II pivotal trial published, reinforcing ‘ transformational value’ of deep vein arterialization in no-option CLTI patients
Results from the PROMISE II pivotal trial investigating transcatheter arterialization of the deep veins using the LimFlow system in so-called no-option chronic limb-threatening ischemia (CLTI) patients were today published in the New England Journal of Medicine (NEJM). The publication confirmed…
Treating PAD: ‘Run, don’t walk, to sign up for this incredible course’
No matter if you’re a surgeon with a few years—or a few decades—of experience, faculty members of a new, upcoming Society for Vascular Surgery course say you’re sure to learn valuable skills and strategies to help in treating patients with…
PROMISE II U.S. pivotal trial of device designed for ‘no-option’ CLTI patients completes enrollment
Enrollment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialization system designed to prevent amputations in so-called “no-option” chronic limb-threatening ischemia (CLTI) patients, the eponymous device maker announced today. “The PROMISE II investigators are…